A new community hub at Orchard Park in Cambridge has opened and charities hope it will help break down barriers to help people access support. The Core community centre was opened by students at ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Issues like increased noise, air pollution and traffic often arise, raising concerns about the impact of industrial parks on ...

Check the time stamp on this data. Updated AI-Generated Signals for Vera Therapeutics Inc. (VERA) available here: VERA. Type ...

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports.

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...